Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Malaysian Genomics Resource Centre Bhd's EV-to-EBIT for today is
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil.
Malaysian Genomics Resource Centre Bhd's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM-0.49 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Malaysian Genomics Resource Centre Bhd's EV-to-EBITDA for today is:
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil.
Malaysian Genomics Resource Centre Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.95 Mil.
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil.
Malaysian Genomics Resource Centre Bhd's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM9.33 Mil.
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil.
Malaysian Genomics Resource Centre Bhd's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.96 Mil.
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil.
Malaysian Genomics Resource Centre Bhd's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd Enterprise Value Related Terms
Malaysian Genomics Resource Centre Bhd Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd Enterprise Value Chart
Malaysian Genomics Resource Centre Bhd Annual Data
XKLS:0155 vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Enterprise Value falls into.
Malaysian Genomics Resource Centre Bhd Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Enterprise Value of RM41.24 Mil as of Jul. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors.
Is Malaysian Genomics Resource Centre Bhd's Enterprise Value too high?
Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Enterprise Value compare to TMO and DHR?
Malaysian Genomics Resource Centre Bhd's Enterprise Value of RM41.24 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current Enterprise Value is RM41.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Fairly Valued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.30 — trading 4.8% below its estimated fair value. The current Enterprise Value is RM41.24 Mil. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Enterprise Value is RM41.24 Mil as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued.
The current stock price of RM0.30 is trading 4.8% below its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Fairly Valued.
Key valuation signals for XKLS:0155:
Enterprise Value: RM41.24 Mil
GF Value™: RM0.31 vs. price of RM0.30 (4.8% below fair value)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd Business Description
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
44GF Score
Get the complete analysis for XKLS:0155
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
